Ny børsmeldinging ute.
Oslo, Norway, 2 February 2017
The Board of Directors of Nordic Nanovector ASA (Nordic Nanovector or the
Company) has on 1th of February 2017 decided to grant 719,500 share options to
employees in accordance with the proxy given by the Annual General Meeting held
on 19 May 2016. Each option, when exercised, will give the right to acquire one
share in Nordic Nanovector. The options are granted without consideration.
The options will expire after 7 years. The vesting schedule means that 25% of
each option holders options will vest 12 months after the day of grant as long
as the option holder is still employed. Thereafter, 1/36 of the remaining
options will vest each month as long as the option holder is still employed,
with the first 1/36 vesting 13 months after the day of grant. The exercise price
of the options is NOK 90.37. The exercise price is equal to the volume weighted
average trading price of the shares of the Company quoted on the Oslo Børs the
last five days prior to the date of the grant.
Primary insiders that were granted options have the following holdings of
options and shares in the Company after the new share options were granted on
1th of February 2017 (new options in parenthesis):
Luigi Costa, CEO holds 1,338,106 options (250,000) and owns 79,115 shares
Tone Kvåle, CFO holds 315,000 options (105,000) and owns 179,608 shares
including shares to related party
Marco Renoldi, COO holds 464,137 options (96,000) and owns 74,000 shares
Anniken Hagen, CTOO holds 177,000 options (35,000) and owns 63,858 shares
Lisa Rojkjaer, CMO holds 375,000 options (35,000) and owns 2,186 shares
Rita Dege, CHRO holds 67,000 options (35,000) and owns 4,754 shares
Jostein Dahle, CSO holds 150,000 options (15,000) and owns 204,958 shares
including shares to related party
The options allocated to the management of the Company is in accordance with the
Board of Directors Declaration on salaries and other remuneration to the senior
executive management, as approved by the Companys annual general meeting held
19 May 2016. The total number of outstanding share options is now 3,509,676
equivalent to 6.7 % of outstanding shares and options on a fully diluted basis.
For further information, please contact:
Tone Kvåle, Chief Financial Officer
Phone: +47 91 51 95 76
E-mail: [email protected]
8 dustetegn 
